 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1995 | Volume 122 Issue 1 | Pages 40-42
Objective: To measure the rate of decrease of the international normalized ratio (INR) after temporary discontinuation of warfarin therapy.
Design: Prospective evaluation of an outpatient cohort.
Setting: University medical center anticoagulation clinic.
Patients: 22 patients receiving a fixed evening dose of warfarin for whom temporary discontinuation of therapy was deemed safe.
Measurements: Serial plasma samples were drawn for INR measurements approximately 20, 65, 115, and 185 hours after patients received the last dose of warfarin. In five patients, INR was measured twice daily for 5 days.
Results: For patients with a mean steady-state INR of 2.6, the mean INR 65 hours (2.7 days) after discontinuation of warfarin therapy was 1.6 (range, 1.11 to 2.16); 20 of 22 patients (91%) had an INR greater than 1.2. The mean INR 115 hours (4.7 days) after discontinuation of warfarin therapy was 1.1; 5 of 22 patients (23%) had an INR of 1.2 or greater. In 5 patients studied in detail, the INR decreased exponentially and had a half-life that ranged from 0.52 to 1.2 days; the onset of maximal decrease began 24 to 36 hours after discontinuation of warfarin therapy. In the total cohort, age was a significant (P < 0.005) independent predictor of smaller decreases in the INR between day 1 and day 3 (regression coefficient = –6.8%±2%/2 days per decade of age; R2 = 0.34).
Conclusions: By simulating preoperative discontinuation of warfarin therapy, we found that the INR decreases exponentially, with wide interpatient variation in the rate of decrease. Age is associated with a slower rate of decrease. To be certain that the INR at the time of the surgery is less than 1.2, warfarin should be withheld for 96 to 115 hours (4 doses) in patients with a steady-state INR between 2.0 and 3.0. For patients with a higher steady-state INR, a longer wait is necessary.
Author and Article Information
From the University of California, Davis, California.
BRIEF COMMUNICATION
Temporary Discontinuation of Warfarin Therapy: Changes in the International Normalized Ratio
Requests for Reprints: Richard H. White, MD, Room 3107 PCC, 2221 Stockton Boulevard, Sacramento, CA 95817.
Acknowledgments: The authors thank Dr. Stephen McCurdy for his careful and thorough review of the manuscript.
This article has been cited by other articles:
|
|
 |
|
  D. Garcia and E. Hylek Factors in Warfarin Therapy Discontinuation--Reply Arch Intern Med, September 22, 2008; 168(17): 1933 - 1933. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Boos and H. J. Marshall Factors in Warfarin Therapy Discontinuation Arch Intern Med, September 22, 2008; 168(17): 1932 - 1932. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Ickx and A. Steib Perioperative management of patients receiving vitamin K antagonists: [Prise en charge perioperatoire des patients traites aux antagonistes de la vitamine K] Can J Anesth, June 1, 2006; 53(6_suppl): S113 - S122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J P Hanley Warfarin reversal J. Clin. Pathol., November 1, 2004; 57(11): 1132 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
|
|
 |
|
 M.J. Kovacs, C. Kearon, M. Rodger, D.R. Anderson, A.G.G. Turpie, S.M. Bates, L. Desjardins, J. Douketis, S.R. Kahn, S. Solymoss, et al. Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin Circulation, September 21, 2004; 110(12): 1658 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bombeli and D. R. Spahn Updates in perioperative coagulation: physiology and management of thromboembolism and haemorrhage Br. J. Anaesth., August 1, 2004; 93(2): 275 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. WALLACE, M. D. LATIMER, and H. J. C. R. BELCHER Stopping Warfarin Therapy is Unnecessary for Hand Surgery J Hand Surg Eur Vol., June 1, 2004; 29(3): 201 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lubetsky, H. Yonath, D. Olchovsky, R. Loebstein, H. Halkin, and D. Ezra Comparison of Oral vs Intravenous Phytonadione (Vitamin K1) in Patients With Excessive Anticoagulation: A Prospective Randomized Controlled Study Arch Intern Med, November 10, 2003; 163(20): 2469 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Manhire, M Charig, C Clelland, F Gleeson, R Miller, H Moss, K Pointon, C Richardson, and E Sawicka Guidelines for radiologically guided lung biopsy Thorax, November 1, 2003; 58(11): 920 - 936. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Hylek, S. Regan, A. S. Go, R. A. Hughes, D. E. Singer, and S. J. Skates Clinical Predictors of Prolonged Delay in Return of the International Normalized Ratio to within the Therapeutic Range after Excessive Anticoagulation with Warfarin Ann Intern Med, September 18, 2001; 135(6): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ginsberg, M. A. Crowther, R. H. White, and T. L. Ortel Anticoagulation Therapy Hematology, January 1, 2001; 2001(1): 339 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, J. Dalen, H. Bussey, D. Anderson, L. Poller, A. Jacobson, D. Deykin, and D. Matchar Managing Oral Anticoagulant Therapy Chest, January 1, 2001; 119(1_suppl): 22S - 38S. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gohlke-Bärwolf VALVE DISEASE: Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery Heart, November 1, 2000; 84(5): 567 - 572. [Full Text]
|
|
|
|
|
|
E. M. Hylek, Y. Chang, S. J. Skates, R. A. Hughes, and D. E. Singer Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation Arch Intern Med, June 12, 2000; 160(11): 1612 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Drugs in the peri-operative period: 4 - Cardiovascular drugs DTB, December 1, 1999; 37(12): 89 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Potyk and P. Raudaskoski Preoperative Cardiac Evaluation for Elective Noncardiac Surgery Arch Fam Med, March 1, 1998; 7(2): 164 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kearon and J. Hirsh Management of Anticoagulation before and after Elective Surgery N. Engl. J. Med., May 22, 1997; 336(21): 1506 - 1511. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh and J. Hoak Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association Circulation, June 15, 1996; 93(12): 2212 - 2245. [Full Text]
|
|
Article
